Table 5.

Susceptibility test results for bloodstream isolates of Candida species

IC₅₀ and IC₉₀ are the concentrations required to inhibit 50 and 90 % of isolates, respectively. MIC breakpoints are according to Clinical and Laboratory Standards Institute method M27-A (NCCLS, 2002). No breakpoints have been set for amphotericin B or caspofungin.

Species (no. tested)	Agent	MIC (μg ml−1)			No. S-DD or I (%)	No. R (%)
		Range	IC50	IC90
C. albicans (153)	Amphotericin B	0.063–1.0	0.50	1.0
	Flucytosine	≤0.13– >64	≤0.13	0.25	2 (1.3)	1 (0.7)
	Fluconazole	≤0.13–16	0.25	0.50	1 (0.7)	0
	Itraconazole	≤0.032–1.0	≤0.032	≤0.032	1 (0.7)	1 (0.7)
	Voriconazole	≤0.032–1.0	≤0.032	≤0.032	0	0
	Caspofungin	≤0.032–1.0	0.063	0.13
C. glabrata (66)	Amphotericin B	0.063–2.0	0.50	1.0
	Flucytosine	≤0.13– >64	≤0.13	≤0.13	0	2 (3.0)
	Fluconazole	≤0.13– >64	16	32	36 (54.5)	4 (6.1)
	Itraconazole	≤0.032– >16	0.50	2.0	27 (40.9)	22 (33.3)
	Voriconazole	≤0.032– >8	0.50	1.0	3 (4.5)	3 (4.5)
	Caspofungin	≤0.032–1.0	0.25	0.50
C. parapsilosis (35)	Amphotericin B	≤0.032–2.0	0.50	1.0
	Flucytosine	≤0.13–32	0.13	0.25	0	2 (5.7)
	Fluconazole	≤0.13–2.0	0.5	1.0	0	0
	Itraconazole	≤0.032–0.25	≤0.032	0.13	2	0
	Voriconazole	≤0.032–0.063	≤0.032	0.063	0	0
	Caspofungin	≤0.032–8.0	1.0	2.0
Other species* (35)	Amphotericin B	0.063–2.0	0.50	1.0
	Flucytosine	≤0.13–32	≤0.13	2.0	0	1 (2.9)
	Fluconazole	≤0.13– >64	1.0	32	5 (14.3)	2 (5.7)
	Itraconazole	≤0.032–0.50	≤0.032	0.25	8 (22.9)	0
	Voriconazole	≤0.032–1.0	0.063	0.5	0	0
	Caspofungin	≤0.032–8.0	0.25	2.0

I, Intermediate; R, resistant.

*C. tropicalis (n=6), C. guilliermondii (n=10), C. krusei (n=3), C. lusitaniae (n=6), C. dubliniensis (n=9), Cryptococcus sp. (n=1).